- Bone Health
- Immunology
- Hematology
- Respiratory
- Dermatology
- Diabetes
- Gastroenterology
- Neurology
- Oncology
- Ophthalmology
- Rare Disease
- Rheumatology
Alvotech and Cipla Partner on 5 Biosimilars for South Africa
Alvotech and Cipla have joined forces to bring biosimilars to treat oncology and autoimmune diseases to South Africa.
Reykjavik, Iceland-based Alvotech has partnered with Cipla Medpro to bring 5 biosimilar candidates to South Africa.
The portfolio will include 2 biosimilar candidates for oncology and 3 for autoimmune diseases; however, the 5 molecules that the biosimilars will reference were not publicly disclosed.
Alvotech will be in charge of development and supply of the products and Cipla will be responsible for commercialization and regulatory registration.
“We’re delighted to establish this important partnership with Cipla…an ideal commercial partner, with a leading presence in the South African pharmaceutical market,” Mark Levick, CEO of Alvotech, said in a statement.
Alvotech’s Other Partners
Alvotech does not have any biosimilars approved yet, but it has been setting other deals for biosimilar distribution with diverse business partners, possibly involving the same biosimilar candidates but in different geographic areas.
In September 2020, Alvotech extended its partnership with DKSH to include distribution of multiple biosimilar products in Asia, the United States, and Europe. Alvotech said this would involve distribution of an adalimumab biosimilar candidate (AVT02).
In August 2020, Alvotech announced a partnership with Teva Pharmaceuticals to commercialize 5 biosimilar candidates for the US market.
Additionally, Avotech has a partnership with JAMP Pharma to market 5 biosimilar candidates in the Canadian market and with Kamada for 6 biosimilar candidates in the Israeli market.
Except for AVT02, Alvotech and its partners have not disclosed any of the molecules included in the deals and there is no information on whether any of the candidates are the same between the deals.
More on Cipla Medpro
Cipla Medpro was founded in South Africa in 1995 under the name Enaleni Pharmaceuticals. Cipla Medpro mostly focuses on over-the-counter and generic medications.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
From Amjevita to Zarxio: A Decade of US Biosimilar Approvals
March 6th 2025Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 originators—though the journey has been anything but smooth, with adoption facing hurdles along the way.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Biosimilar Approvals Streamlined With Advanced Statistics Amidst Differing Regulatory Requirements
February 25th 2025The FDA and European Medicines Agency (EMA) mandate high similarity between biosimilars and reference products, but their regulatory processes differ, especially with multiple reference products.
